LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
NRXP
NRx Pharmaceuticals, Inc.
There isn't enough reported data to score NRXP yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
NRXP Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Unavailable |
NRXP's profitability and cash flow are currently weak. There isn't enough data to rate its revenue and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
NRXP PE Valuation
NRXP has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over NRXP on the outlook, with more favorable earnings and profitability expectations.
NRXP Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect NRXP's losses to grow, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the stronger earnings trend. Trailing diluted EPS is up 51% for LLY versus NRXP down 206%.
NRXP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$2.29 | -$0.12 |
| Q2 2025 | -$2.17 | +$0.55 |
| Q1 2025 | -$1.94 | +$1.23 |
| Q4 2024 | -$2.36 | +$1.67 |
| Q3 2024 | -$2.17 | +$2.83 |
| Q2 2024 | -$2.72 | +$2.98 |
| Q1 2024 | -$3.17 | +$2.43 |
| Q4 2023 | -$4.03 | +$1.97 |
NRXP is still losing money, but far less than before: $2.29 per share over the past year, against $19.00 at its worst in mid-2022.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over NRXP on profitability, with a higher operating margin.
NRXP Quarterly Revenue
NRXP's revenue has grown year over year every quarter since late 2025: $1M last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -591% | N/A |
| Q1 2026 | -444% | N/A |
| Q4 2025 | -470% | N/A |
| Q3 2025 | -1663% | N/A |
LLY has the edge over NRXP on profitability, with a higher operating margin.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with NRXP at up 25%.
NRXP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$4.3M | -$815K |
| Q4 2025 | -$3.7M | -$1.6M |
| Q3 2025 | -$2.9M | -$585K |
| Q4 2024 | -$2.1M | +$1.1M |
| Q3 2024 | -$2.3M | +$2.3M |
| Q4 2023 | -$3.2M | +$5.1M |
| Q3 2023 | -$4.6M | +$1.7M |
| Q2 2023 | -$7.8M | +$7M |
NRXP has burned cash in almost every quarter: −$15M over the past year, against −$11M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over NRXP on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
NRXP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +16% | +5.3M shares |
| 1 year | +118% | +20.4M shares |
| 3 years | +472% | +31.1M shares |
| 5 years | +13858% | +37.4M shares |
| Available history | +13340% | +37.4M shares |
NRXP has 38M diluted shares, up 118% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2020 | $299,253 |
| Q2 2020 | — |
| Q1 2020 | $26M |
| Q3 2019 | $8.9M |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
NRXP Net Leverage
NRXP's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
NRXP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.1 | Neutral |
| Stochastic | 10.6 | Oversold |
NRXP's weekly RSI is 36 (neutral) and its Stochastic is 11 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
NRXP PE vs Healthcare Sector
| Metric | NRXP | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
NRXP has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over NRXP on trend strength, trading above more of its moving averages.
NRXP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.60 | 12% below |
| 20 week MA | $3.21 | 29% below |
| 50 week MA | $2.85 | 20% below |
| 100 week MA | $2.78 | 18% below |
| 200 week MA | $3.47 | 34% below |
NRXP is in a downtrend: it's below all five of its weekly moving averages, and 34% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over NRXP on returns for 2026, with the stronger performance.
NRXP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $106.5 | $296.4 | +178% |
| 2021 | $296.4 | $50.4 | -83% |
| 2022 | $50.4 | $10.8 | -79% |
| 2023 | $10.8 | $4.60 | -57% |
| 2024 | $4.60 | $1.51 | -67% |
| 2025 | $1.51 | $2.56 | +70% |
| 2026 YTD | $2.56 | $2.28 | -11% |
NRXP's yearly returns have swung widely, from +178% in 2020 to −83% in 2021. It's down 11% so far in 2026.